Neurodiagnostics Market Report 2026

The neurodiagnostics market size has grown strongly in recent years. It will grow from $9.79 billion in 2025 to $10.46 billion in 2026 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to increased incidence of neurological disorders, early adoption of mri and ct scanning, development of eeg and emg systems, rising demand for stroke diagnosis tools, growth in hospital-based neurodiagnostic infrastructure.

The neurodiagnostics market size is expected to see strong growth in the next few years. It will grow to $13.48 billion in 2030 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to expansion of biomarker-based diagnostics, increasing investment in neuroimaging innovation, rising adoption of digital neuroinformatics platforms, development of portable and wearable neurodiagnostic devices, growing demand for point-of-care neurological testing. Major trends in the forecast period include increasing adoption of advanced neuroimaging modalities, growing use of in-vitro neurodiagnostic biomarkers, rising demand for early detection of neurological disorders, expansion of eeg and meg for real-time brain monitoring, increasing focus on non-invasive and minimally invasive diagnostics.

The rising prevalence of neurological disorders is expected to drive the growth of the neurodiagnostics market in the coming years. Neurological disorders are conditions affecting the brain, spinal cord, or peripheral nerves, resulting in a range of cognitive, motor, and sensory impairments. Factors contributing to this increase include aging populations, environmental influences, lifestyle changes, genetic predispositions, and improvements in diagnostic techniques. Neurodiagnostic tools are crucial for accurately identifying, assessing, and monitoring these disorders, enabling precise diagnoses, informed treatment decisions, and effective management of neurological conditions. For example, in April 2023, the National Library of Medicine, a US-based medical research resource, reported that 6.7 million Americans were affected by Alzheimer’s disease, with this number projected to rise to 13.8 million by 2060. Therefore, the growing prevalence of neurological disorders is boosting the neurodiagnostics market.

Leading companies in the neurodiagnostics market are focusing on technological innovations such as advanced AI-driven software algorithms to enhance diagnostic accuracy and improve patient outcomes. These algorithms process and analyze complex medical data using artificial intelligence and machine learning techniques, providing clinicians with actionable insights for better decision-making. For instance, in October 2023, Ceribell Inc., a US-based medical device manufacturer, launched the ClarityPro AI algorithm, a major advancement in diagnosing electrographic status epilepticus (ESE). Integrated into the Ceribell EEG system, ClarityPro uses machine learning to continuously analyze EEG waveforms and provide real-time alerts for suspected seizures. It is the first acute care device to receive FDA clearance for standalone diagnosis and is designed to support faster, more accurate treatment responses by offering continuous brain monitoring and actionable insights.

In October 2025, Natus Medical Incorporated, a US-based medical device company, acquired Holberg EEG for an undisclosed amount. This acquisition aims to strengthen Natus’s neurodiagnostic capabilities by integrating Holberg’s advanced AI-driven EEG interpretation technology into its product portfolio, enhancing diagnostic precision and workflow efficiency. Holberg EEG is a Norway-based company specializing in AI-powered electroencephalogram interpretation solutions.

Major companies operating in the neurodiagnostics market are Nihon Kohden Corporation, Cephalon LLC, Stratus Neuro LLC, Cadwell Industries Inc., Compumedics Limited, Ceribell Inc., CND Life Sciences Inc., Lifelines Neuro Inc., ANT Neuro B.V., Neurovative Diagnostics LLC, Firefly Neuroscience Inc, IntraNerve Neuroscience Inc, NeuroDiagnostics Laboratories LLC, Advanced Brain Monitoring Inc, Spes Medica S.r.l., BioSignal Group Inc, Combinostics Inc., Deymed Diagnostic LLC, NeuLine Health Inc., Ridge Diagnostics Inc., Beacon Biosignals Inc., Intch Inc.

North America was the largest region in the neurodiagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurodiagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the neurodiagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the neurodiagnostics market by raising the cost of imported MRI systems, CT scanners, EEG devices, and diagnostic reagents essential for neurological testing. These cost increases particularly affect hospitals, imaging centers, and diagnostic laboratories in regions dependent on imported imaging hardware, particularly Asia-Pacific and Europe. Segments such as neuroimaging technologies and in-vitro diagnostics face procurement delays, higher installation costs, and reduced accessibility. However, tariffs also encourage local manufacturing of imaging components and diagnostic kits, fostering regional innovation and reducing long-term dependency on international suppliers.

The neurodiagnostics market research report is one of a series of new reports that provides neurodiagnostics market statistics, including neurodiagnostics industry global market size, regional shares, competitors with a neurodiagnostics market share, detailed neurodiagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the neurodiagnostics industry. This neurodiagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Neurodiagnostics refers to the specialized medical field dedicated to diagnosing, monitoring, and managing disorders of the nervous system, including the brain, spinal cord, and peripheral nerves. It employs advanced technologies and diagnostic tests to evaluate neurological function, detect abnormalities, and support the diagnosis and treatment of conditions such as epilepsy, stroke, multiple sclerosis, neuropathies, Alzheimer’s disease, Parkinson’s disease, and other neurological disorders.

The main types of neurodiagnostics include diagnostic and imaging solutions and in-vitro diagnostics. Diagnostic and imaging solutions encompass technologies and services that assess neurological health through various imaging and diagnostic modalities. Key technologies include neuroimaging, computed tomography (CT), magnetic resonance imaging (MRI), nuclear medicine imaging (PET, SPECT), near-infrared spectroscopic imaging (NIRS), electroencephalography (EEG), magnetoencephalography (MEG), voxel-based morphometry (VBM), and neuroinformatics. In-vitro diagnostics involve laboratory-based tests that detect biomarkers or other indicators in blood, cerebrospinal fluid, or tissue samples to aid in neurological assessment. These tools are applied in hospitals, clinics, diagnostic laboratories, imaging centers, and other healthcare settings to guide treatment and improve patient outcomes.

The neurodiagnostics market includes revenues earned by entities by providing services such as electroencephalography (EEG), positron emission tomography (PET), cerebrospinal fluid (CSF) analysis, and sleep apnea diagnosis. The market value includes the value of related goods sold by the service provider or included within the service offering. The neurodiagnostic market consists of sales of transcranial magnetic stimulation (TMS) devices, magnetoencephalography (MEG) systems, polysomnography (PSG) devices, and biosensors. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.